Watch MRNA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
34
FLAG · insiders 31, shorts 36
Insiders, 90 days
−$486K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $58.1BP/E —DIV YIELD —FCF YIELD -2.14%REV TTM $2.2B −27.6%NET INCOME −$3.2BNET CASH $1.1B52W 22.36 – 174.38SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $145M | +2.1% | 35.9% | −$815M | −$782M | — | -1.97 | −$526M | $37M | −$563M | Jul 31 |
| Q1 2026 · Mar 31 | $389M | +260.2% | -145.5% | −$1.4B | −$1.3B | — | -3.40 | −$630M | $62M | −$692M | May 1 |
| Q4 2025 · Dec 31derived | $678M | −29.8% | 33.3% | −$857M | −$826M | — | -2.11 | $930M | $39M | $891M | Feb 20 |
| Q3 2025 · Sep 30 | $1B | −45.4% | 79.6% | −$260M | −$200M | −1638.5% | -0.51 | −$847M | $33M | −$880M | Nov 6 |
| Q2 2025 · Jun 30 | $142M | −41.1% | 16.2% | −$907M | −$825M | — | -2.13 | −$919M | $3M | −$922M | Jul 31 |
| Q1 2025 · Mar 31 | $108M | −35.3% | 16.7% | −$1.1B | −$971M | — | -2.52 | −$1B | $117M | −$1.2B | May 1 |
| Q4 2024 · Dec 31derived | $966M | −65.6% | 23.5% | −$1.2B | −$1.1B | −616.1% | -2.91 | $825M | $522M | $303M | Feb 20 |
| Q3 2024 · Sep 30 | $1.9B | +1.7% | 72.4% | −$70M | $13M | — | 0.03 | −$1.6B | $151M | −$1.7B | Nov 6 |
| Q2 2024 · Jun 30 | $241M | — | 52.3% | −$1.4B | −$1.3B | — | -3.33 | −$1.3B | $182M | −$1.5B | Aug 1 |
| Q1 2024 · Mar 31 | $167M | — | 42.5% | −$1.3B | −$1.2B | — | -3.07 | −$989M | $196M | −$1.2B | May 1 |
| Q4 2023 · Dec 31derived | $2.8B | — | 67.0% | $6M | $217M | — | 0.56 | $622M | $220M | $402M | Feb 20 |
| Q3 2023 · Sep 30 | $1.8B | — | -22.4% | −$2B | −$3.6B | — | -9.53 | −$1.6B | $140M | −$1.7B | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.9B | 55.3% | −$3.1B | −$2.8B | -145.2% | -7.26 | −$1.9B | $192M | −$2.1B | $2M | — |
| FY2024 · to Dec 31 | $3.2B | 54.8% | −$3.9B | −$3.6B | -110.0% | -9.28 | −$3B | $1.1B | −$4.1B | $0 | — |
| FY2023 · to Dec 31 | $6.8B | 31.5% | −$4.2B | −$4.7B | -68.8% | -12.33 | −$3.1B | $707M | −$3.8B | $1.2B | — |
| FY2022 · to Dec 31 | $19.3B | 71.9% | $9.4B | $8.4B | 43.4% | 20.12 | $5B | $400M | $4.6B | $3.3B | — |
| FY2021 · to Dec 31 | $18.5B | 85.8% | $13.3B | $12.2B | 66.1% | 28.29 | $13.6B | $284M | $13.3B | $857M | — |
| FY2020 · to Dec 31 | $803M | 99.0% | −$763M | −$747M | -93.0% | -1.96 | $2B | $68M | $2B | $0 | — |
Every number comes from Moderna, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.